Cell-based vaccination vs mortality-reducing therapies Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging … more ➔
AI predicts mutations underlying neurological diseases Using data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease. more ➔
F2G bags €50.8m financing to advance olorofimUK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors. more ➔
Evotec receives $8.4m CARB-X fundingEvotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic. more ➔
The new role of communications in times of coronaCOVID-19 has put life science research companies into the limelight. An Interview with Raimund Gabriel, founder and managing director MC Services AG, on the role of corporate communications in the corona … more ➔
The end of partnering events as we know themAn ongoing crisis and evolving new working habits of industry executives call for an entirely new and up-to-date partnering format. Workarounds such as moving a partnering event’s scheduled one-on-one … more ➔
BioNTech and Fosun Pharma kick off Chinese COVID-19 trialsBioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials. more ➔
Evotec partners with Secarna to develop LNA drugsEvotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline. more ➔
Rapid test for pandemics Rapid tests have received a lot of attention during the Coronavirus pandemic, but as the number of tests available has increased, so has the confusion around the different types and what they can deliver. … more ➔
EC secures 300 million doses of COVID-19 vaccineThe European Commission has reserved 300 million doses from Sanofi SA’/GSK plc’s adjuvanted recombinant COVID-19 vaccine. more ➔
